KR20240018697A - 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신 - Google Patents

면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신 Download PDF

Info

Publication number
KR20240018697A
KR20240018697A KR1020247004035A KR20247004035A KR20240018697A KR 20240018697 A KR20240018697 A KR 20240018697A KR 1020247004035 A KR1020247004035 A KR 1020247004035A KR 20247004035 A KR20247004035 A KR 20247004035A KR 20240018697 A KR20240018697 A KR 20240018697A
Authority
KR
South Korea
Prior art keywords
group
polysaccharides
capsular
kda
streptococcus pneumoniae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247004035A
Other languages
English (en)
Korean (ko)
Inventor
수브하쉬 브이. 카프레
아누프 케이. 다타
Original Assignee
인벤트프라이즈 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인벤트프라이즈 인크. filed Critical 인벤트프라이즈 인크.
Publication of KR20240018697A publication Critical patent/KR20240018697A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247004035A 2017-06-10 2018-06-11 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신 Pending KR20240018697A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762517905P 2017-06-10 2017-06-10
US62/517,905 2017-06-10
PCT/US2018/036868 WO2018227177A1 (en) 2017-06-10 2018-06-11 Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity
KR1020207000802A KR102634811B1 (ko) 2017-06-10 2018-06-11 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207000802A Division KR102634811B1 (ko) 2017-06-10 2018-06-11 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신

Publications (1)

Publication Number Publication Date
KR20240018697A true KR20240018697A (ko) 2024-02-13

Family

ID=64562792

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020247004035A Pending KR20240018697A (ko) 2017-06-10 2018-06-11 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신
KR1020247004036A Pending KR20240018698A (ko) 2017-06-10 2018-06-11 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신
KR1020207000802A Active KR102634811B1 (ko) 2017-06-10 2018-06-11 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020247004036A Pending KR20240018698A (ko) 2017-06-10 2018-06-11 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신
KR1020207000802A Active KR102634811B1 (ko) 2017-06-10 2018-06-11 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신

Country Status (12)

Country Link
US (1) US10688170B2 (enExample)
EP (1) EP3634481A4 (enExample)
JP (1) JP7132954B2 (enExample)
KR (3) KR20240018697A (enExample)
CN (2) CN118356485A (enExample)
AU (1) AU2018280272C1 (enExample)
BR (1) BR112019026192B1 (enExample)
CA (1) CA3066911C (enExample)
MX (2) MX2019014829A (enExample)
MY (1) MY198400A (enExample)
WO (1) WO2018227177A1 (enExample)
ZA (1) ZA201908528B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016248452B2 (en) * 2015-04-16 2018-05-31 Inventprise, Inc. Bordetella pertussis immunogenic vaccine compositions
IL303998A (en) * 2015-07-21 2023-08-01 Pfizer Immunogenic preparations containing conjugated capsular sugar antigens, kits containing them and their uses
US10729763B2 (en) * 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
MX2019014829A (es) 2017-06-10 2020-08-17 Inventprise Llc Vacunas de conjugado multivalente con polisacáridos de conjugado bivalente o multivalente que proporcionan inmunogenicidad y avidez mejoradas.
KR102686858B1 (ko) 2017-12-06 2024-07-19 머크 샤프 앤드 돔 엘엘씨 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체를 포함하는 조성물 및 그의 사용 방법
US20220016229A1 (en) * 2018-12-12 2022-01-20 Pfizer Inc. Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
WO2020131763A2 (en) 2018-12-19 2020-06-25 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
AU2020286360A1 (en) * 2019-06-05 2021-12-23 Merck Sharp & Dohme Llc An immunogenic serotype 35B pneumococcal polysaccharide-protein conjugate and conjugation process for making the same
CN110804097B (zh) * 2019-10-30 2021-02-26 云南沃森生物技术股份有限公司 一种同时制备两种单克隆抗体的方法
AU2021207701B2 (en) * 2020-01-17 2025-08-14 Bill & Melinda Gates Foundation Multivalent Streptococcus vaccines
CN111643661A (zh) * 2020-06-08 2020-09-11 王竹林 新型免疫佐剂、化合物及其应用
WO2022035816A1 (en) * 2020-08-10 2022-02-17 Inventprise, Llc Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
US20240000912A1 (en) * 2020-11-04 2024-01-04 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CN113173977B (zh) * 2021-05-12 2024-03-29 江苏坤力生物制药有限责任公司 一种双功能抗原、其制备方法及应用
CN115721709A (zh) * 2021-08-27 2023-03-03 康希诺生物股份公司 一种肺炎球菌结合疫苗制备方法
GB2614916A (en) 2022-01-25 2023-07-26 Optivalent Ltd Intradermal vaccine complement
CN118871591A (zh) * 2022-03-18 2024-10-29 电化株式会社 包含通过接头连接的衣壳蛋白的病毒样颗粒
CN117643624A (zh) * 2024-01-30 2024-03-05 成都康华生物制品股份有限公司 一种双价多糖结合疫苗的制备方法及双价多糖结合疫苗

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360897A (en) 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4686102A (en) 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
US5371197A (en) 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
US5849301A (en) 1993-09-22 1998-12-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5681570A (en) 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
US5866132A (en) 1995-06-07 1999-02-02 Alberta Research Council Immunogenic oligosaccharide compositions
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US6224880B1 (en) 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
US5965714A (en) 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6903184B1 (en) 1998-03-02 2005-06-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Multiple antigenic peptides immunogenic against Streptococcus pneumonia
CN1200731C (zh) 1998-04-07 2005-05-11 免疫医疗公司 用作疫苗的肺炎球菌胆碱结合蛋白衍生物
EP1034792A1 (en) 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
DK1163000T3 (da) 1999-03-19 2008-04-28 Glaxosmithkline Biolog Sa Vacciner imod antigener fra bakterier
FR2806304B1 (fr) 2000-03-17 2002-05-10 Aventis Pasteur Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0130215D0 (en) 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
AU2003239744B2 (en) 2002-05-14 2008-07-03 Novartis Vaccines And Diagnostics S.R.L. Mucosal combination vaccines for bacterial meningitis
WO2004000802A2 (en) 2002-06-20 2003-12-31 University Of Maryland Biotechnology Institute Scaffolded maleimide clusters for multivalent peptide assembly
US20040096461A1 (en) * 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
KR101052996B1 (ko) 2003-03-13 2011-07-29 글락소스미스클라인 바이오로지칼즈 에스.에이. 박테리아 세포용해소에 대한 정제 공정
CA2948114C (en) 2003-08-06 2019-02-26 Che-Hung Robert Lee Polysaccharide-protein conjugate vaccines
US8048432B2 (en) 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
US20050118199A1 (en) 2003-10-07 2005-06-02 Esser Mark T. Process for covalently conjugating polysaccharides to microspheres or biomolecules
US20090317412A1 (en) * 2004-06-04 2009-12-24 Alexander Jeffery L Induction of an immune response against streptococcus pneumoniae polyaccharides
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
EP2425856A1 (en) 2005-04-08 2012-03-07 Wyeth LLC Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
ES2443529T3 (es) 2005-09-01 2014-02-19 Novartis Vaccines And Diagnostics Gmbh Vacunación múltiple incluyendo meningococo del serogrupo C
DK2384765T3 (en) 2005-12-22 2017-01-09 Glaxosmithkline Biologicals Sa Vaccine against Streptococcus pneumoniae.
GB0607088D0 (en) * 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
US8481054B2 (en) 2005-12-28 2013-07-09 The UAB Foundation Pneumococcal serotypes
DK1976974T3 (da) 2005-12-28 2014-09-15 Uab Research Foundation Pneumokok-serotyper.
WO2007106435A2 (en) 2006-03-10 2007-09-20 University Of California Cleavable vaccines compositions and methods of making and using the same
KR20150038626A (ko) 2006-03-17 2015-04-08 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 복합 다가 면역원성 콘쥬게이트의 제조 방법
AR060187A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Composicion inmunogenica
US20070253985A1 (en) 2006-04-26 2007-11-01 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
MX2009001412A (es) * 2006-08-07 2009-04-24 Harvard College Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
EP2129693B1 (en) 2007-03-23 2016-12-07 Wyeth LLC Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides
WO2008157590A1 (en) * 2007-06-20 2008-12-24 Baxter International Inc. Modified polysaccharides for conjugate vaccines
EP2687228B1 (en) 2007-06-26 2017-07-19 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
US8226959B2 (en) 2008-02-01 2012-07-24 Newcastle Innovation Pty Ltd Vaccine compositions
EP2108656A1 (en) 2008-03-19 2009-10-14 Beninati, Concetta Antigenic protein fragments of streptococcus pneumoniae
DK2379734T3 (en) 2008-12-18 2018-04-23 Wyeth Llc Method for Controlling the Molecular Weight of Polysaccharide of Streptococcus Pneumoniae Serotype 19A
KR101450958B1 (ko) 2009-04-30 2014-10-15 콜레이 파마시티컬 그룹, 인코포레이티드 폐렴구균 백신 및 그의 용도
WO2010141312A2 (en) 2009-06-01 2010-12-09 Wake Forest University Health Sciences Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
BR112012005349A2 (pt) 2009-09-09 2016-03-29 Matrivax Res & Dev Corp composição imunogênica, seu método de fabricação, método de fabricação de uma composição de vacina de matriz de proteína, e uso
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
AU2011262346B2 (en) 2010-06-04 2014-12-11 Wyeth Llc Streptococcus pneumoniae vaccine formulations
US10766932B2 (en) 2011-05-11 2020-09-08 The Children's Medical Center Corporation Multiple antigen presenting immunogenic composition, and methods and uses thereof
JP6460789B2 (ja) 2011-06-03 2019-01-30 スリーエム イノベイティブ プロパティズ カンパニー ポリエチレングリコールセグメントを有するヘテロ２官能性リンカー及び該リンカーから調製された免疫反応調節複合体
WO2014013375A1 (en) * 2012-07-16 2014-01-23 Pfizer Inc. Saccharides and uses thereof
EP3421051B1 (en) * 2012-08-16 2020-05-13 Pfizer Inc Glycoconjugation processes and compositions
CN103656631B (zh) * 2012-09-24 2015-08-19 北京科兴中维生物技术有限公司 多价肺炎球菌荚膜多糖-蛋白缀合物组合物及其制备方法
GB201218660D0 (en) * 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
SI2935299T1 (sl) 2012-12-20 2019-12-31 Pfizer Inc. Postopek glikokonjugacije
ITMI20130142A1 (it) 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
US20150079132A1 (en) 2013-09-17 2015-03-19 Path Evoking protection against streptotoccus pneumoniae incorporating b-cell and t-cell pneumococcal protein antigens and pneumococcal polysaccharides delivered concomitantly
EP3096785B1 (en) * 2014-01-21 2020-09-09 Pfizer Inc Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
HRP20211288T1 (hr) 2014-01-21 2021-11-26 Pfizer Inc. Kapsularni polisaharidi bakterije streptococcus pneumoniae i njihovi konjugati
PT3096783T (pt) 2014-01-21 2021-08-16 Pfizer Polissacáridos capsulares de streptococcus pneumoniae e conjugados dos mesmos
EP3443983B1 (en) * 2014-02-14 2022-07-20 Pfizer Inc. Immunogenic glycoprotein conjugates
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
CN104069504B (zh) * 2014-05-11 2019-09-24 江苏康泰生物医学技术有限公司 一种增强多糖蛋白结合物免疫原性的方法
US20150344530A1 (en) 2014-05-29 2015-12-03 Subhash V. Kapre Synthetic Peptides as Carriers for Conjugation with Polysaccharides
SG11201702451WA (en) 2014-10-09 2017-04-27 Msd Wellcome Trust Hilleman Lab Pvt Ltd An improved process of conjugation and novel synthetic oligosaccharide- protein conjugates obtained thereof
LT3313436T (lt) * 2015-06-23 2021-06-10 Biological E Limited Daugiavalentė pneumokokinė konjuguota vakcina
IL303998A (en) 2015-07-21 2023-08-01 Pfizer Immunogenic preparations containing conjugated capsular sugar antigens, kits containing them and their uses
EP3377098A1 (en) * 2015-11-20 2018-09-26 Pfizer Inc Immunogenic compositions for use in pneumococcal vaccines
MX2019014829A (es) 2017-06-10 2020-08-17 Inventprise Llc Vacunas de conjugado multivalente con polisacáridos de conjugado bivalente o multivalente que proporcionan inmunogenicidad y avidez mejoradas.

Also Published As

Publication number Publication date
MY198400A (en) 2023-08-28
WO2018227177A1 (en) 2018-12-13
JP2020523323A (ja) 2020-08-06
AU2018280272C1 (en) 2021-05-06
KR102634811B1 (ko) 2024-02-06
JP7132954B2 (ja) 2022-09-07
KR20240018698A (ko) 2024-02-13
ZA201908528B (en) 2020-09-30
CN111132691A (zh) 2020-05-08
CA3066911A1 (en) 2018-12-13
BR112019026192B1 (pt) 2022-05-10
AU2018280272A1 (en) 2020-01-30
BR112019026192A2 (pt) 2020-06-30
EP3634481A4 (en) 2021-07-21
MX2019014829A (es) 2020-08-17
CA3066911C (en) 2022-05-24
MX2023009362A (es) 2023-08-16
KR20200014921A (ko) 2020-02-11
CN118356485A (zh) 2024-07-19
US10688170B2 (en) 2020-06-23
EP3634481A1 (en) 2020-04-15
US20180353591A1 (en) 2018-12-13
AU2018280272B2 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
KR102634811B1 (ko) 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신
US11376323B2 (en) Mixtures of polysaccharide protein pegylated compounds
KR102225282B1 (ko) 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
JP6808658B2 (ja) 多価肺炎球菌コンジュゲートワクチン
RU2634405C2 (ru) Иммуногенная композиция
CZ285650B6 (cs) Způsob přípravy kovalentního konjugátu oligosacharidu a nosičového proteinu
US12053515B2 (en) Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F
US7812006B2 (en) Conjugates obtained by reductive amination of the pneumococcus serotype 5 capsular polysaccharide
AU2021207701A1 (en) Multivalent Streptococcus vaccines
US20250195640A1 (en) Immunogenic Compositions of Polysaccharide-Protein Pegylated Compounds
KR20200005458A (ko) 다가 폐렴구균 다당체-단백질 접합체를 포함하는 면역원성 조성물, 및 이를 포함하는 약학 조성물
HK40023130B (zh) 包含缀合荚膜糖抗原的免疫原性组合物及其用途
HK40021072B (zh) 包含缀合荚膜糖抗原的免疫原性组合物及其用途

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240202

Application number text: 1020207000802

Filing date: 20200110

PA0201 Request for examination
PG1501 Laying open of application